1Altman J D,Moss P A H,Goulder P J R et al.Phenotypic analysis of antigen-specific T lymphocytes[J].Science,1996;274(5284):94-96.
2Yee C,Savage P A,Lee P P et al.Isolation of high avidlity melanoma-reactive CTL from heterogeneous populations using peptide-MHC tetramers[J].J Immunol,1999;162(4):2227-2234.
3Mackensen A,Veelken H,Lahn M et al.Induction of tumorspecific cytotoxic T lymphocytes by immunization with autologous tumor cells and interleukin-2 gene transfected fibroblasts[J].J Mol Med,1997;75:290-296.
4Kalams S A,Johnson R P,Trocha A K et al.Longitudinal analysis of T-cell receptor(TCR) gene usage by human immunodeficiency virus 1 envelope-specific cytotoxic T lymphocyte clones reveals a limited TCR repertoire[J].J Exp Med,1994;179:1261-1271.
5McKee M D,Clay T M,Rosenberg S A et al.Quantitation of T-cell receptor frequencies by competitive PCR:generation and evaluation of novel TCR subfamily and clone specific competitors[J].J Immunother,1999;22:93-102.
6Kourilsky P,Bousso P,Calbo S et al.Immunological issues in vaccine trials:T-cell response[J].Dev Biol Stand,1998;95:117-124.
7Lue C,Mitani Y,Crew M D et al.An automated method for the analysis of T-cell receptor repertoires:rapid RT-PCR fragment length analysis of the T-cell receptor β chain complementarity-determining region 3[J].Am J Chin Pathol,1999;111:683-690.
8Disis M L,Grabstein K H,Sleath P R et al.Generation of immunity to the HER-2/neu oncogenic protein in patients with breast and ovarian cancer using a peptide-based vaccine[J].Clin Cancer Res,1999;5:1289-1297.
9Schreiber S,Kampgen E,Wagner E et al.Immunotherapy of metastatic malignant melanoma by a vaccine consisting of autologous interleukin-2-transfected caner cells:outcome of a phase I study[J].Hum Gene Ther,1999;10:983-993.
10Khleif S N,Abrams S I ,Hamilton et al.A phase I vaccine trial with peptides reflecting ras oncogene mutations of solid tumors[J].J Immunother,1999;22:155-165.
